Gifthealth

After the FDA’s March 2026 crackdown on compounded GLP-1s, virtually no major telehealth services still openly offer them, with most having stopped entirely or transitioned to FDA-approved commercial alternatives like Wegovy, Ozempic, and Zepbound[1][2]. However, there is one explicitly named service that has indicated it may continue providing compounded doses under specific clinical conditions, though the situation involves conflicting reports on its current status: Service Status on Compounded GLP-1s Key Details Hims & Hers Conditional/Limited Access (Disputed) Initially claimed it would continue offering personalized compounded doses for patients with specific medical needs (e.g., unavailable dosages or allergies) citing "loopholes" for incremental dosing[2][7]. However, other reports state Hims & Hers exited compounded semaglutide entirely in March 2026 after settling with Novo Nordisk and becoming an authorized Wegovy/Ozempic distributor[9][10]. Ro Stopped Ro now offers Zepbound via LillyDirect and has stopped offering compounded GLP-1s[2][5]. Noom Stopped Noom transitioned to partnering with LillyDirect for commercial Zepbound and Gifthealth for FDA-approved single-dose vials[2][5]. (Note: An older report mentioned Noom offered compounded Wegovy in May, but this was likely before the full enforcement or was a microdosing initiative that has since been superseded by commercial partnerships)[6]. Novelty/Firewall Firms Likely Active Smaller, non-prominent firms (e.g., Refills, Fifty410, Lovely Meds, Hello Cake) were explicitly named in FDA warning letters, suggesting they may still be operating or attempting to navigate regulations despite the crackdown[1][13]. Key Context for Your Decision The "Shortage" Loophole is Closed: The FDA officially declared the shortages of branded GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) as ended, removing the primary legal justification telehealth firms used for compounding identical copies[6][8]. Enforcement is Ongoing: The FDA issued an additional wave of 25 warning letters in June 2026, confirming that aggressive enforcement continues against telehealth marketing of compounded products[5]. Recommended Alternative: For reliable and safe access, experts recommend using FDA-approved options through providers like LillyDirect (via Ro), Noom (with Gifthealth), or Hims & Hers (now an authorized Wegovy distributor)[2][10]. Conclusion: If you are looking for a major, reputable telehealth platform that currently and confidently offers compounded GLP-1s, none exist in the current landscape. Hims & Hers is the only entity that previously claimed to offer a conditional exception, but recent reports suggest they have also ceased these sales. Any remaining access is likely limited to smaller, less regulated firms that have been explicitly warned by the FDA.

Mentioned in position 9 of 9

The telehealth services that explicitly offer Zepbound (tirzepatide) include LifeMD and Teladoc Health, which have partnered directly with Eli Lilly to provide reduced-cost, single-vial Zepbound through their full-service weight loss programs[2][5]. Other major providers offering Zepbound include Ro Body, PlushCare, Noom Med, Hers, Calibrate, LifeMD, Walgreens Weight Management, LillyDirect (via affiliated telehealth), Doctronic.ai, Form Health, and Ivim Health[3][4][5][6][9]. Specific recommendations by name and value: LifeMD: Offers Zepbound from $75/month with health coaching, a weight loss program, and a money-back guarantee; it’s one of the most affordable and well-integrated options[2][5]. Teladoc Health: Partners with Eli Lilly for lower-cost Zepbound via conditional self-pay pharmacy (GiftHealth), serving tens of thousands of patients[2]. Ro Body: Provides Zepbound at $45 for the first month, then $145/month, with health coaching and insurance concierge services[5]. PlushCare: Offers a $129 initial consultation plus $19.99/monthmonthly membership, with unlimited messaging and lab discounts[4][5]. Walgreens Weight Management: No subscription required; initial video visit starts at $49, and Zepbound is available in the new multi-dose KwikPen starting at $299/month[6]. Ivim Health: Users report successfully obtaining multiple Zepbound boxes through this service, with insurance collaboration and a total cost of around $100/month (including prescription)[1]. These services allow you to get a Zepbound prescription online without an in-person visit, provided you meet eligibility criteria (BMI ≥30 or ≥27 with weight-related conditions) and your state’s telehealth laws permit it[3][6].

Mentioned in position 13 of 13

LifeMD and Teladoc Health are the primary telehealth services that officially offer the reduced-cost, branded Zepbound (tirzepatide) through a direct partnership with Eli Lilly [3]. Several other reputable telehealth providers also offer access to Zepbound, often through their affiliated weight management programs or by prescribing it via independent telehealth networks: Ro Body (Ro): Offers Zepbound with ongoing support and an insurance concierge to help with coverage [4]. PlushCare: Provides Zepbound via monthly membership, with same-day consultations and access to single-use vials through LillyDirect for cash-pay buyers [4][5]. Weight Watchers Clinic: A personalized treatment option that includes Zepbound and offers insurance coordination [4][9]. Form Health: Listed by Eli Lilly as an independent telehealth option for obesity care that offers Zepbound [9]. Walgreens Weight Management: Allows you to start a virtual visit to potentially receive a Zepbound prescription, which can be picked up at Walgreens [6]. Noom Med: Offers Zepbound alongside lifestyle and behavioral support [4]. Calibrate: Provides Zepbound with personalized video coaching [4]. Ivim Health: A user-reported provider where patients have successfully obtained Zepbound, often working with insurance [2]. Sesame Care (offered via Costco): Provides access to Zepbound, with a specific cost of $179 for 3 months for Costco members who accept FSA/HSA [2]. Recommendation: If you are seeking the lowest official self-pay price for branded Zepbound vials, LifeMD and Teladoc are the top choices due to their direct contract with Eli Lilly's self-pay pharmacy, GiftHealth [3]. For those prioritizing insurance coverage or personalized coaching, Ro Body, Weight Watchers Clinic, and Calibrate are strong alternatives [4].

Mentioned in position 14 of 14

Very few major telehealth services still openly offer compounded GLP-1s after the FDA’s March 2026 crackdown; most have either stopped offering them or transitioned to FDA-approved commercial alternatives like Wegovy, Ozempic, Saxenda, or Zepbound[1][2]. However, Hims & Hers has indicated it may continue providing personalized (compounded) doses of semaglutide for customers when clinically appropriate, citing “loopholes” for incremental dosages not commercially available[5][7]. This is the only prominently named service explicitly confirming continued access to compounded GLP-1s under specific conditions. Key distinctions: Stopped compounded GLP-1s: Ro, Noom (now partner with LillyDirect for commercial Zepbound), and most other major providers[1][5]. Transitioned to commercial products: Ro now offers Zepbound via LillyDirect; Noom partners with Gifthealth for single-dose vials of FDA-approved drugs[5]. Limited/conditional continued access: Hims & Hers claims to offer personalized compounded doses where commercially unavailable formulations are needed[5]. ⚠️ Important caution: The FDA has issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1s, emphasizing that compounded drugs are not FDA-approved, and their safety, effectiveness, and quality are unreviewed[2][3]. Any service claiming compounded GLP-1s are equivalent to FDA-approved products is likely in violation[1][4]. For reliable and safe access, consider FDA-approved options through providers like LillyDirect (Ro), Noom (with Gifthealth), or traditional telehealth platforms that prescribe Wegovy, Ozempic, or Zepbound. If you require a non-standard dose, consult a licensed prescriber who can evaluate whether compounding is legally permissible under FDA exceptions (e.g., drug shortage or allergy) [1].

Mentioned in position 5 of 5